Truist lowered the firm’s price target on Evolent Health (EVH) to $15 from $20 and keeps a Buy rating on the shares. The firm is updating its model after the company’s investor healthcare conference last week, noting that given the elevated level of utilization that Evolent experienced in November and lack of clarity into December trends, it is reducing its Q4 EBITDA estimates from $30M to $24M, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $20 from $29 at BTIG
- Evolent Health price target lowered to $12 from $16 at Stephens
- Evolent Health price target lowered to $14 from $27 at UBS
- Evolent Health reiterates long-term outlook, says FY25 guide coming February 20
- Evolent dips after Truist warns guidance may be ‘significantly’ below consensus